Economic Evaluations of Pharmacogenetic and Pharmacogenomic Screening Tests: A Systematic Review. Second Update of the Literature
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Economic Evaluations of Pharmacogenetic and Pharmacogenomic Screening Tests: A Systematic Review. Second Update of the Literature
Authors
Keywords
Cost-effectiveness analysis, Pharmacogenetics, Economics, Genetic testing, Drug screening, Genetic polymorphism, Genotyping, Pharmacoeconomics
Journal
PLoS One
Volume 11, Issue 1, Pages e0146262
Publisher
Public Library of Science (PLoS)
Online
2016-01-12
DOI
10.1371/journal.pone.0146262
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cost-Effectiveness of UGT1A1*28 Genotyping in Preventing Severe Neutropenia Following FOLFIRI Therapy in Colorectal Cancer.
- (2016) Solen Pichereau et al. JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES
- HEALTH TECHNOLOGY ASSESSMENT AND PERSONALIZED MEDICINE: ARE ECONOMIC EVALUATION GUIDELINES SUFFICIENT TO SUPPORT DECISION MAKING?
- (2014) Don Husereau et al. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE
- Is Individualized Medicine More Cost-Effective? A Systematic Review
- (2014) Maximilian H. M. Hatz et al. PHARMACOECONOMICS
- The Cost-Effectiveness of a Pharmacogenetic Test: A Trial-Based Evaluation of TPMT Genotyping for Azathioprine
- (2014) Alexander J. Thompson et al. VALUE IN HEALTH
- Cost-Effectiveness of Using Pharmacogenetic Information in Warfarin Dosing for Patients With Nonvalvular Atrial Fibrillation
- (2013) Mark H. Eckman ANNALS OF INTERNAL MEDICINE
- New Protease Inhibitors for the Treatment of Chronic Hepatitis C
- (2013) Shan Liu et al. ANNALS OF INTERNAL MEDICINE
- Cost-Effectiveness of Pharmacogenetics-Guided Warfarin Therapy vs. Alternative Anticoagulation in Atrial Fibrillation
- (2013) J Pink et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Economic evaluation of HLA-B*15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand
- (2013) Waranya Rattanavipapong et al. EPILEPSIA
- Challenges in pharmacogenetics
- (2013) Ingolf Cascorbi et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- The economic value of personalized medicine tests: what we know and what we need to know
- (2013) Kathryn A Phillips et al. GENETICS IN MEDICINE
- Cost Effectiveness of Targeted High-dose Atorvastatin Therapy Following Genotype Testing in Patients with Acute Coronary Syndrome
- (2013) Anju Parthan et al. PHARMACOECONOMICS
- Pharmacogenetic-guided selection of warfarin versus novel oral anticoagulants for stroke prevention in patients with atrial fibrillation
- (2013) Joyce H.S. You Pharmacogenetics and Genomics
- Cost–effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillation
- (2013) Talitha I Verhoef et al. PHARMACOGENOMICS
- Cost–effectiveness of using CYP2C19 genotype to guide selection of clopidogrel or ticagrelor in Australia
- (2013) Michael J Sorich et al. PHARMACOGENOMICS
- The Cloudy Crystal Ball of Cost-Effectiveness Studies
- (2013) Gerardus W.J. Frederix et al. VALUE IN HEALTH
- Cost minimization of HLA-B*1502 screening before prescribing carbamazepine in Thailand
- (2013) Somsak Tiamkao et al. International Journal of Clinical Pharmacy
- Cost-effectiveness analysis of UGT1A1 genetic testing to inform antiretroviral prescribing in HIV disease
- (2012) Bruce R Schackman et al. ANTIVIRAL THERAPY
- Implementing Personalized Medicine: Development of a Cost-Effective Customized Pharmacogenetics Genotyping Array
- (2012) J A Johnson et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Cost-Effectiveness Model of Use of Genetic Testing as an Aid in Assessing the Likely Benefit of Aspirin Therapy for Primary Prevention of Cardiovascular Disease
- (2012) Dov Shiffman et al. CLINICAL THERAPEUTICS
- Economic Evaluations Conducted for Assessment of Genetic Testing Technologies: A Systematic Review
- (2012) Nazila Assasi et al. Genetic Testing and Molecular Biomarkers
- Cost-Effectiveness Analysis of Screening for KRAS and BRAF Mutations in Metastatic Colorectal Cancer
- (2012) Ajay S. Behl et al. JNCI-Journal of the National Cancer Institute
- Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis
- (2012) A. LALA et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Cost-Effectiveness Analysis of KRAS Testing and Cetuximab as Last-Line Therapy for Colorectal Cancer
- (2012) Takeru Shiroiwa et al. Molecular Diagnosis & Therapy
- Genetic Testing in Combination with Preventive Donepezil Treatment for Patients with Amnestic Mild Cognitive Impairment
- (2012) Sandjar Djalalov et al. Molecular Diagnosis & Therapy
- Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore
- (2012) D. Dong et al. NEUROLOGY
- The Cost Effectiveness of Genetic Testing for CYP2C19 Variants to Guide Thienopyridine Treatment in Patients with Acute Coronary Syndromes
- (2012) Laura Panattoni et al. PHARMACOECONOMICS
- Cost–effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs
- (2012) Talitha I Verhoef et al. PHARMACOGENOMICS
- Cost-Effectiveness of Cytochrome P450 2C19 Genotype Screening for Selection of Antiplatelet Therapy with Clopidogrel or Prasugrel
- (2012) Emily S. Reese et al. PHARMACOTHERAPY
- Cost-Effectiveness of Dabigatran versus Genotype-Guided Management of Warfarin Therapy for Stroke Prevention in Patients with Atrial Fibrillation
- (2012) Joyce H. S. You et al. PLoS One
- Cost Effectiveness of Personalized Therapy for First-Line Treatment of Stage IV and Recurrent Incurable Adenocarcinoma of the Lung
- (2012) Elizabeth A. Handorf et al. Journal of Oncology Practice
- Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung
- (2011) Gilberto de Lima Lopes et al. CANCER
- KRAS and BRAF Mutation Analysis in Metastatic Colorectal Cancer: A Cost-effectiveness Analysis from a Swiss Perspective
- (2011) P. R. Blank et al. CLINICAL CANCER RESEARCH
- The Cost-Effectiveness of Personalized Genetic Medicine: The case of genetic testing in neonatal diabetes
- (2011) S. A. W. Greeley et al. DIABETES CARE
- A review of economic evaluations of genetic testing services and interventions (2004–2009)
- (2011) Sandjar Djalalov et al. GENETICS IN MEDICINE
- Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany
- (2011) Arthi Vijayaraghavan et al. INTERNATIONAL JOURNAL OF CANCER
- Economic Evaluation of Genomic Test–Directed Chemotherapy for Early-Stage Lymph Node–Positive Breast Cancer
- (2011) Peter S. Hall et al. JNCI-Journal of the National Cancer Institute
- Effects of Family History and Genetic Polymorphism on the Cost-Effectiveness of Chemoprevention With Finasteride for Prostate Cancer
- (2011) Shelby D. Reed et al. JOURNAL OF UROLOGY
- A cost effectiveness analysis of thiopurine methyltransferase testing for guiding 6-mercaptopurine dosing in children with acute lymphoblastic leukemia
- (2011) Jennifer R. Donnan et al. PEDIATRIC BLOOD & CANCER
- Should pharmacogenetics be incorporated in major depression treatment? Economic evaluation in high- and middle-income European countries
- (2011) Paolo Olgiati et al. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
- Ticagrelor versus Genotype-Driven Antiplatelet Therapy for Secondary Prevention after Acute Coronary Syndrome: A Cost-Effectiveness Analysis
- (2011) Daniel J. Crespin et al. VALUE IN HEALTH
- A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders
- (2011) Alessandro Serretti et al. WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY
- Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost–effectiveness analysis of different predictive assay strategies
- (2010) Patricia R. Blank et al. BREAST CANCER RESEARCH AND TREATMENT
- Economic evaluations of pharmacogenetic and genomic screening programs: update of the literature
- (2010) Stefan Vegter et al. DRUG DEVELOPMENT RESEARCH
- Thiopurine S-Methyltranferase Testing in Idiopathic Pulmonary Fibrosis: A Pharmacogenetic Cost-Effectiveness Analysis
- (2010) Jared T. Hagaman et al. LUNG
- Economic Efficiency of Genetic Screening to Inform the Use of Abacavir Sulfate in the Treatment of HIV
- (2010) Teresa L. Kauf et al. PHARMACOECONOMICS
- Cost Effectiveness of Pharmacogenomics
- (2010) William B. Wong et al. PHARMACOECONOMICS
- Systematic review of pharmacoeconomic studies of pharmacogenomic tests
- (2010) Mathieu Beaulieu et al. PHARMACOGENOMICS
- Potential economic impact of the 21-gene expression assay on the treatment of breast cancer in brazil
- (2010) Carlos Eduardo Bacchi et al. Revista da Associacao Medica Brasileira
- Economic Implications of 21-Gene Breast Cancer Risk Assay from the Perspective of an Israeli-Managed Health-Care Organization
- (2010) Shmuel H. Klang et al. VALUE IN HEALTH
- Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer
- (2009) Heather Taffet Gold et al. CANCER
- Economic Analysis of Gene Expression Profile Data to Guide Adjuvant Treatment in Women with Early-Stage Breast Cancer
- (2009) Leon E. Cosler et al. CANCER INVESTIGATION
- Cost-Effectiveness of Genotype-Guided Warfarin Dosing for Patients With Atrial Fibrillation
- (2009) Amanda R. Patrick et al.
- Potential Clinical and Economic Outcomes of CYP2C9 and VKORC1 Genotype-Guided Dosing in Patients Starting Warfarin Therapy
- (2009) J H S You et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- When is Pharmacogenetic Testing for Antidepressant Response Ready for the Clinic? A Cost-effectiveness Analysis Based on Data from the STAR*D Study
- (2009) Roy H Perlis et al. NEUROPSYCHOPHARMACOLOGY
- Pharmacoeconomic Evaluations of Pharmacogenetic and Genomic Screening Programmes
- (2009) Stefan Vegter et al. PHARMACOECONOMICS
- Clinical Effectiveness and Cost Effectiveness of Tailoring Chronic Hepatitis C Treatment with Peginterferon Alpha-2b Plus Ribavirin to HCV Genotype and Early Viral Response
- (2009) Uwe Siebert et al. PHARMACOECONOMICS
- A Policy Model to Evaluate the Benefits, Risks and Costs of Warfarin Pharmacogenomic Testing
- (2009) Lisa M. Meckley et al. PHARMACOECONOMICS
- Cost-effectiveness of ACE inhibitor therapy to prevent dialysis in nondiabetic nephropathy: influence of the ACE insertion/deletion polymorphism
- (2009) Stefan Vegter et al. Pharmacogenetics and Genomics
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. PLOS MEDICINE
- Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer
- (2008) Mathias Lidgren et al. ACTA ONCOLOGICA
- The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV
- (2008) Bruce R Schackman et al. AIDS
- A Review of Public Policy Issues in Promoting the Development and Commercialization of Pharmacogenomic Applications: Challenges and Implications
- (2008) Louis P. Garrison et al. DRUG METABOLISM REVIEWS
- A cost-effectiveness analysis of genetic testing of the DRD2 Taq1A polymorphism to aid treatment choice for smoking cessation
- (2008) Nicky Welton et al. NICOTINE & TOBACCO RESEARCH
- The Potential Clinical and Economic Outcomes of Pharmacogenomic Approaches to EGFR-Tyrosine Kinase Inhibitor Therapy in Non–Small-Cell Lung Cancer
- (2008) Josh J. Carlson et al. VALUE IN HEALTH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started